As opposed to conventional continuous exposure to MEK inhibitors in the clinic, a pulsatile schedule of MEK inhibitors (selumetinib and trametinib) was more effective at controlling tumor progression and altering the tumor microenvironment favorably by enhancing T cell activation with increased expression of immune checkpoint regulators CTLA-4 and PD-1. Here, PDCD1 is linked to neoplasm.